119 related articles for article (PubMed ID: 37779238)
21. Construction and Validation of an Immune-Related lncRNA Prognosis Model for Thyroid Cancer.
Li Z; Wang H; Deng X; Zhang J; Wang L; Tang W; You W; Nian W
Comb Chem High Throughput Screen; 2022; 25(13):2217-2227. PubMed ID: 35209814
[TBL] [Abstract][Full Text] [Related]
22. Anoikis-related gene CDKN2A predicts prognosis and immune response and mediates proliferation and migration in thyroid carcinoma.
Tang M; Luo W; Zhou Y; Zhang Z; Jiang Z
Transl Oncol; 2024 Feb; 40():101873. PubMed ID: 38141377
[TBL] [Abstract][Full Text] [Related]
23. Identification of PANoptosis-related genes as prognostic indicators of thyroid cancer.
Xie D; Huang L; Li C; Wu R; Zheng Z; Liu F; Cheng H
Heliyon; 2024 Jun; 10(11):e31707. PubMed ID: 38845990
[TBL] [Abstract][Full Text] [Related]
24. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371
[TBL] [Abstract][Full Text] [Related]
25. DNAJB11 predicts a poor prognosis and is associated with immune infiltration in thyroid carcinoma: a bioinformatics analysis.
Sun R; Yang L; Wang Y; Zhang Y; Ke J; Zhao D
J Int Med Res; 2021 Nov; 49(11):3000605211053722. PubMed ID: 34727750
[TBL] [Abstract][Full Text] [Related]
26. DPP4 Is a Potential Prognostic Marker of Thyroid Carcinoma and a Target for Immunotherapy.
Gao X; Le Y; Geng C; Jiang Z; Zhao G; Zhang P
Int J Endocrinol; 2022; 2022():5181386. PubMed ID: 36467461
[TBL] [Abstract][Full Text] [Related]
27. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Role of Mitochondrial Transcription Termination Factor 3 in Thyroid Carcinoma.
Sun MT; Zhao HY; Ruan HJ; Yu LH; Guan ML; Fan JJ; Feng CZ; Lou YY
Genet Test Mol Biomarkers; 2023 Dec; 27(12):362-369. PubMed ID: 38156906
[No Abstract] [Full Text] [Related]
29. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
[TBL] [Abstract][Full Text] [Related]
30. NKD2 is correlated with the occurrence, progression and prognosis of thyroid carcinoma.
Gao Y; Wang Y; Guo R
Eur J Med Res; 2022 Nov; 27(1):235. PubMed ID: 36348408
[TBL] [Abstract][Full Text] [Related]
31. Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.
Wu P; Shi J; Wang Z; Sun W; Zhang H
Cancer Cell Int; 2022 Oct; 22(1):307. PubMed ID: 36217201
[TBL] [Abstract][Full Text] [Related]
32. CAPN8 involves with exhausted, inflamed, and desert immune microenvironment to influence the metastasis of thyroid cancer.
Zhong X; Xu S; Wang Q; Peng L; Wang F; He T; Liu C; Ni S; He Z
Front Immunol; 2022; 13():1013049. PubMed ID: 36389799
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma.
Shi Y; Sheng P; Guo M; Chen K; Zhou H; Wu M; Li W; Li B
Front Genet; 2023; 14():1100909. PubMed ID: 37470034
[No Abstract] [Full Text] [Related]
34. High expression of
Luo X; Chen X; Chen S; Gao Q; Yang H; Zhao D
Gland Surg; 2022 Feb; 11(2):412-425. PubMed ID: 35284305
[TBL] [Abstract][Full Text] [Related]
35. Construction and validation of a PANoptosis-related lncRNA signature for predicting prognosis and targeted drug response in thyroid cancer.
Li R; Zhao M; Sun M; Miao C; Lu J
PeerJ; 2023; 11():e15884. PubMed ID: 37671354
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer.
Zhu Y; Yu T; Huang J; Ma X; Shen T; Li A; Yue R
Am J Cancer Res; 2022; 12(7):3259-3279. PubMed ID: 35968348
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
Shen R; Liu B; Li X; Yu T; Xu K; Ma J
BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
[TBL] [Abstract][Full Text] [Related]
38. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.
Long M; Zhou Z; Wei X; Lin Q; Qiu M; Zhou Y; Chen P; Jiang Y; Wen Q; Liu Y; Li R; Zhou X; Yu H
Front Immunol; 2022; 13():1023349. PubMed ID: 36353638
[TBL] [Abstract][Full Text] [Related]
39. A seven-autophagy-related gene signature for predicting the prognosis of differentiated thyroid carcinoma.
Li C; Yuan Q; Xu G; Yang Q; Hou J; Zheng L; Wu G
World J Surg Oncol; 2022 Apr; 20(1):129. PubMed ID: 35459137
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer.
Wu P; Shi J; Sun W; Zhang H
Cancer Cell Int; 2021 Oct; 21(1):523. PubMed ID: 34627252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
